World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
92
Citations
59864
World Ranking
11062
National Ranking
5691

Overview

What is she best known for?

The fields of study she is best known for:

  • Cancer
  • Internal medicine
  • Gene

Kanti R. Rai mostly deals with Chronic lymphocytic leukemia, Immunology, Leukemia, Internal medicine and Antibody. Her Chronic lymphocytic leukemia study combines topics in areas such as Cancer research, Clinical trial, Untreated Chronic Lymphocytic Leukemia, Fludarabine and Disease. Her work deals with themes such as Telomere, Telomerase and Gene mutation, which intersect with Immunology.

Her work carried out in the field of Leukemia brings together such families of science as Lymphoma, In vivo and CD38. Her Internal medicine study combines topics from a wide range of disciplines, such as Gastroenterology, Surgery and Oncology. The study incorporates disciplines such as T cell and breakpoint cluster region in addition to Antibody.

Her most cited work include:

  • Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia (4145 citations)
  • Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines (2519 citations)
  • Clinical staging of chronic lymphocytic leukemia. (2355 citations)

What are the main themes of her work throughout her whole career to date?

Her primary scientific interests are in Chronic lymphocytic leukemia, Immunology, Internal medicine, Cancer research and Leukemia. Her primary area of study in Chronic lymphocytic leukemia is in the field of IGHV@. Immunology is closely attributed to Disease in her study.

Her research investigates the connection between Internal medicine and topics such as Oncology that intersect with problems in Clinical trial. Her Cancer research study incorporates themes from Cell, Cytokine, Cell growth, Ibrutinib and Interleukin 15. Breakpoint cluster region is closely connected to Antigen in her research, which is encompassed under the umbrella topic of Antibody.

She most often published in these fields:

  • Chronic lymphocytic leukemia (99.20%)
  • Immunology (58.45%)
  • Internal medicine (38.17%)

What were the highlights of her more recent work (between 2013-2021)?

  • Chronic lymphocytic leukemia (99.20%)
  • Cancer research (45.73%)
  • Immunology (58.45%)

In recent papers she was focusing on the following fields of study:

Kanti R. Rai mainly investigates Chronic lymphocytic leukemia, Cancer research, Immunology, Internal medicine and Leukemia. Her studies deal with areas such as breakpoint cluster region and CD5, Antibody as well as Chronic lymphocytic leukemia. The concepts of her Cancer research study are interwoven with issues in In vitro, Cytokine, Cell growth, T cell and Interleukin 15.

Her Immunology study frequently draws parallels with other fields, such as Myeloid-derived Suppressor Cell. Her research in Internal medicine intersects with topics in Gastroenterology, Surgery and Oncology. In her study, Clinical trial is inextricably linked to Disease, which falls within the broad field of Leukemia.

Between 2013 and 2021, her most popular works were:

  • iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL (392 citations)
  • Chronic lymphocytic leukaemia. (192 citations)
  • Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia (159 citations)

In her most recent research, the most cited papers focused on:

  • Cancer
  • Internal medicine
  • Gene

Kanti R. Rai spends much of her time researching Chronic lymphocytic leukemia, Immunology, Leukemia, Internal medicine and Cancer research. Kanti R. Rai studies Ibrutinib which is a part of Chronic lymphocytic leukemia. Her study in T cell, Antibody and B-cell receptor falls within the category of Immunology.

Her Leukemia research integrates issues from Somatic cell, Bruton's tyrosine kinase, Pathogenesis and Somatic evolution in cancer. Her biological study spans a wide range of topics, including Gastroenterology, Surgery and Oncology. Her Cancer research research includes themes of Tyrosine kinase, CD5, DNA methylation and CD38.

Best Publications

  • Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia

    George Adrian Calin;Calin Dan Dumitru;Masayoshi Shimizu;Roberta Bichi

  • Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines

    Michael Hallek;Bruce D. Cheson;Daniel Catovsky;Federico Caligaris-Cappio

  • Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.

    Rajendra N. Damle;Tarun Wasil;Tarun Wasil;Tarun Wasil;Franco Fais;Franco Fais;Franco Fais;Fabio Ghiotto;Fabio Ghiotto;Fabio Ghiotto

  • Clinical staging of chronic lymphocytic leukemia.

    Kanti R. Rai;Arthur Sawitsky;Eugene P. Cronkite;Arjun D. Chanana

  • National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment

    Bruce D. Cheson;John M. Bennett;Michael Grever;Neil Kay

  • Chronic lymphocytic leukemia.

    Nicholas Chiorazzi;Kanti R. Rai;Manlio Ferrarini

  • Chronic Lymphocytic Leukemia.

    Nicholas Chiorazzi;Shih-Shih Chen;Kanti R. Rai

  • iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL

    Michael Hallek;Bruce D. Cheson;Daniel Catovsky;Federico Caligaris-Cappio

  • Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

    Kanti R. Rai;Bercedis L. Peterson;Frederick R. Appelbaum;Jonathan Kolitz

  • Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.

    Michael J. Keating;Ian Flinn;Vinay Jain;Jacques-Louis Binet

  • ZAP-70 Compared with Immunoglobulin Heavy-Chain Gene Mutation Status as a Predictor of Disease Progression in Chronic Lymphocytic Leukemia

    Laura Z. Rassenti;Lang Huynh;Tracy L. Toy;Liguang Chen

  • Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors.

    Franco Fais;Fabio Ghiotto;Shiori Hashimoto;Brian Sellars

  • Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: Correlations with in vitro and in vivo chemoresponses

    Shinichi Kitada;Janet Andersen;Sophie Akar;Juan M. Zapata

  • Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).

    John C. Byrd;Bercedis L. Peterson;Vicki A. Morrison;Kathleen Park

  • In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells.

    Bradley T. Messmer;Davorka Messmer;Steven L. Allen;Steven L. Allen;Jonathan E. Kolitz;Jonathan E. Kolitz

  • Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia.

    Liguang Chen;George Widhopf;George Widhopf;George Widhopf;Lang Huynh;Lang Huynh;Lang Huynh;Laura Rassenti;Laura Rassenti;Laura Rassenti

  • Chronic lymphocytic leukaemia.

    Thomas J. Kipps;Freda K. Stevenson;Catherine J. Wu;Carlo M. Croce

  • Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.

    John C. Byrd;Kanti Rai;Bercedis L. Peterson;Frederick R. Appelbaum

  • Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B.

    KR Rai;JF Holland;OJ Glidewell;V Weinberg

  • Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the national cancer institute-sponsored working group

    Bruce D. Cheson;John M. Bennett;Kanti R. Rai;Michael R. Grever

Frequent Co-Authors

Nicholas Chiorazzi
Nicholas Chiorazzi Feinstein Institute for Medical Research
Jonathan E. Kolitz
Jonathan E. Kolitz Hofstra University
Thomas J. Kipps
Thomas J. Kipps University of California, San Diego
John C. Byrd
John C. Byrd University of Pittsburgh Cancer Institute
Laura Z. Rassenti
Laura Z. Rassenti University of California, San Diego
Jennifer R. Brown
Jennifer R. Brown Harvard University
Michael J. Keating
Michael J. Keating The University of Texas MD Anderson Cancer Center
Neil E. Kay
Neil E. Kay Mayo Clinic
John G. Gribben
John G. Gribben Queen Mary University of London
Richard A. Larson
Richard A. Larson University of Chicago

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a medical career in the USA doesn't just mean attending traditional medical school. Many healthcare professionals explore flexible online degrees to expand their skills or pivot into new roles. For registered nurses interested in a mental health specialty, bsn to np programs online offer accelerated paths to become nurse practitioners with a psychiatric-mental health focus.

If you're drawn to leadership and policy, a health care administration online degree is an effective way to enter the fast-growing field of healthcare management. For those seeking to advance their careers further, consider one of the most affordable online mha programs, which can open doors to senior roles across diverse healthcare settings.

Practicing nurses aiming for the highest level of clinical expertise may benefit from msn to dnp programs online. These programs prepare you for leadership and advanced practice roles while accommodating busy work schedules. Exploring these online pathways offers accessibility, flexibility, and a variety of specialized career options within medicine and healthcare.

Best Scientists Citing Kanti R. Rai

Trending Scientists

Recently Published Articles